title: Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
abstract: We present a 42-year-old man who was admitted with worsening of his general condition and facial skin lesions. He had previously been diagnosed with HIV infection and visceral leishmaniasis (VL). Diagnostic work-up revealed a new relapse of VL paralleled by the diagnosis of post-kala-azar dermal leishmaniasis (PKDL). The patient was treated with IV liposomal amphotericin B as well as sodium stibogluconate followed by oral hexadecylphosphocholine (miltefosine) over a period of 9 months. PKDL lesions began to disappear after 8 months of treatment. In addition, severe and relapsing VL so far remains in remission. This case demonstrates successful treatment of PKDL and relapsing VL in a Western European patient with HIV infection.
authors.affiliation: Department of Rheumatology (OE 6850), Hannover Medical School (MHH), Carl-Neuberg-Str. 1, 30625 Hannover, Germany. rihl.markus@mh-hannover.de
authors.forename: Markus
authors.initials: M
authors.lastname: Rihl
authors.forename: Matthias
authors.initials: M
authors.lastname: Stoll
authors.forename: Kai
authors.initials: K
authors.lastname: Ulbricht
authors.forename: Franz-Christoph
authors.initials: FC
authors.lastname: Bange
authors.forename: Reinhold-Ernst
authors.initials: RE
authors.lastname: Schmidt
mesh_terms: D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D000967:Antimony Sodium Gluconate / Q000008:administration & dosage / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005060:Europe; D005858:Germany; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D016773:Leishmaniasis, Cutaneous / Q000150:complications / Q000188:drug therapy* / Q000469:parasitology; D007898:Leishmaniasis, Visceral / Q000150:complications* / Q000469:parasitology; D008081:Liposomes / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D010767:Phosphorylcholine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000981:Antiprotozoal Agents; D008081:Liposomes; C068538:liposomal amphotericin B; D010767:Phosphorylcholine; C039128:miltefosine; D000666:Amphotericin B; D000967:Antimony Sodium Gluconate